Ton Lisman: New JTH Guidance for Authors
Ton Lisman, Professor of Experimental Surgery at UMC Groningen, shared a post on LinkedIn about a recent article he and Suzanne Cannegieter co-authored, published in JTH, adding:
“Suzanne Cannegieter and I have outlined recent changes we made in the instructions to authors for submission to Journal of Thrombosis and Haemostasis (JTH) in this editorial.
We are thrilled to see our field is thriving as evidenced by a substantial increase in the number of high-quality submissions to Journal of Thrombosis and Haemostasis (JTH).
However, this substantial increase in workload for our team forces us to carefully consider which submissions are of sufficient interest to undergo peer review.
We encourage all working in the field of Thrombosis and Hemostasis to send your best work to Journal of Thrombosis and Haemostasis (JTH) for publication consideration.
We hope our updated instructions to authors are helpful to understand what types of manuscripts we are looking for.”
Title: More and More
Authors: Ton Lisman, Suzanne C. Cannegieter

Stay updated with Hemostasis Today.
-
Nov 13, 2026, 16:17Shailendra Singh: Bombay Hospital Jaipur Inaugurates New Facility with Voluntary Blood Donation Camp
-
Nov 13, 2026, 16:10Minka Zivkovic: UMC Utrecht Announces Research Analyst Vacancy in Thrombosis and Haemostasis
-
Nov 13, 2026, 16:02Rounak Dubey: Elsevier’s Upcoming Handbook Explores Digitalization in Transfusion Medicine
-
Nov 13, 2026, 15:50Maha Othman: CanVECTOR 2026 Highlights Research on Immunothrombosis and Cancer-Associated Thrombosis
-
Nov 13, 2026, 15:48Cedric Hermans: Advances in Gene Therapy for Haemophilia A
-
Nov 13, 2026, 15:45Strengthens Global Collaboration in Thrombosis and Hemostasis for 2027 – ISTH
-
Nov 13, 2026, 15:42David McIntosh: The Global Blood Shortage Crisis and the Urgent Need for National Action
-
Nov 13, 2026, 15:41JTH Highlights Future Directions in Thromboprophylaxis for Hospitalized Children
-
Nov 13, 2026, 15:21Wolfgang Miesbach։ Gene Therapy for Haemophilia B Is Cheaper Than Lifelong Factor IX Prophylaxis in Sweden